Bowel preparations containing oral so− dium phosphate have gained increased favor among gastroenterology endosco− pists in preference to the traditional poly− ethylene glycol, likely due to greater pa− tient tolerability and improved cleansing and compliance [1] . Despite the availabil− ity of reports in the literature concerning life−threatening metabolic and cardiac abnormalities associated with the use of oral sodium phosphate in patients with renal insufficiency, less than half of re− spondents in a recent survey among gas− trointestinal endoscopists reported its ex− clusion in this patient population [2] . We report two cases of severe hyperphospha− temia and secondary hypocalcemia due to administration of an oral sodium phos− phate−containing bowel preparation in patients with chronic renal insufficiency.
Bowel preparations containing oral so− dium phosphate have gained increased favor among gastroenterology endosco− pists in preference to the traditional poly− ethylene glycol, likely due to greater pa− tient tolerability and improved cleansing and compliance [1] . Despite the availabil− ity of reports in the literature concerning life−threatening metabolic and cardiac abnormalities associated with the use of oral sodium phosphate in patients with renal insufficiency, less than half of re− spondents in a recent survey among gas− trointestinal endoscopists reported its ex− clusion in this patient population [2] . We report two cases of severe hyperphospha− temia and secondary hypocalcemia due to administration of an oral sodium phos− phate−containing bowel preparation in patients with chronic renal insufficiency.
The first patient, a 51−year−old woman with end−stage renal disease requiring peritoneal dialysis, was evaluated for gen− eralized weakness, perioral tingling, elici− table Chvosteks sign, and a prolonged QT interval. The patient had ingested two 45− ml doses of Fleets Phospho−Soda solution the previous night, in preparation for a screening colonoscopy. Laboratory evalu− ation revealed abnormal levels of calcium and phosphate in comparison with base− line values ( Figure 1 ). Clinical symptoms and laboratory abnormalities of hypocal− cemic tetany resolved rapidly after the pa− tient received intravenous calcium and peritoneal dialysis. The patient subse− quently underwent colonoscopy without any complications and continued to be asymptomatic on follow−up.
The second patient was a 57−year−old man with diabetes mellitus and chronic renal insufficiency who presented with hema− tochezia. Laboratory values on admission were unremarkable except for a serum creatinine of 2.1 mg/dl. At 2 days after in− gesting two doses of 45 ml of oral sodium phosphate for a colonoscopy, his metabol− ic profile demonstrated serum calcium and phosphate of 6.5 mg/dl and16.9 mg/ dl, respectively (Figure 1) . He remained asymptomatic and received oral calcium acetate to bind phosphate. The patient was discharged in a stable condition with serum calcium and phosphate of 6.7 mg/ dl and 14.4 mg/dl, respectively. No fol− low−up information was available.
Similar abnormalities in serum calcium and phosphate, associated with oral so− dium phosphate ingestion, have been re− ported in the absence of renal insufficien− cy. This may, however, be related to the dosage of oral sodium phosphate admi− nistered (greater than 90 ml) or to im− paired bowel motility leading to pro− longed intestinal transit time [3] . A 45− ml bottle of oral sodium phosphate con− tains approximately 6 g of inorganic phos− phate, while a person with normal renal function can handle an intake of phos− phate up to 4 g over a 24−hour period, due to reduced proximal tubular reab− sorption of phosphate [4] . A rise in serum phosphate is thought to be the primary etiology of hypocalcaemia in these pa− tients [5] .
Previously published literature does not report the magnitude of renal insufficien− cy that would raise concern about the re− nal ability to handle the phosphate load present in the oral sodium phosphate. Based on available information about phosphate metabolism, and the kinetics of renal handling of phosphate, one can postulate that a creatinine clearance £ 50 ml/min or serum creatinine of > 2.0 mg/dl may lead to significant hyper− phosphatemia following the ingestion of a single dose of oral sodium phosphate containing a phosphate load of 6 g. Care− ful attention should be paid when select− ing bowel−cleansing preparations for co− lonoscopy in patients with renal insuffi− ciency. UCT N Unusual Cases and Technical Notes
